10月15日，荣昌生物（09995）股价盘中大涨5.03%，引发市场关注。
消息面上，荣昌生物当日宣布，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普（商品名：泰爱®）用于治疗原发性免疫球蛋白A（IgA）肾病的上市申请，已获国家药品监督管理局药品审评中心（CDE）受理，并纳入优先审评程序。这一消息显然提振了投资者信心。
值得注意的是，泰它西普成为IgA肾病领域首个申报上市的国产原研新药，这凸显了荣昌生物在该治疗领域的领先地位。此外，公司表示，申报的剂型为泰它西普注射液（预充式注射器装），这将为患者提供更加便捷的给药方式，有望进一步提高产品的市场竞争力。这些因素共同推动了荣昌生物股价的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.